The control of microvascular permeability and blood pressure by neutral endopeptidase

Nature Medicine

Volumn 3, Issue 8, 1997, Pages 904-907

  Lu, Bao ^a   Figini, Michela ^b   Emanueli, Costanza ^b   Geppetti, Pierangelo ^b   Grady, Eileen F ^c   Gerard, Norma P ^a   Ansell, John ^d   Payan, Donald G ^c   Gerard, Craig ^a   Bunnett, Nigel ^c,e  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE METALLOENDOPEPTIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; ENZYME REGULATION; GENE DISRUPTION; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANIMALS; BLOOD PRESSURE; BRADYKININ; CAPILLARIES; CAPILLARY PERMEABILITY; FEMALE; MALE; MICE; MICE, INBRED C57BL; NEPRILYSIN; RECEPTORS, BRADYKININ; RECEPTORS, NEUROKININ-1; SUBSTANCE P; VENULES;

ANIMALIA;

EID: 0030790063     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0897-904     Document Type: Article

References (26)

1. Payan, D. Substance P. in Inflammation: Basic Principles and Clinical Correlates (eds. Gallin, J.I., Goldstein, I.M. & Snyderman, R.) 177-191 (Raven, New York, 1992).
2. Von Euler, U.S. & Gaddum, J.H. An unidentified depressor substance in certain tissue extracts, J. Physiol. (Lond.) 72, 74-87 (1931).
3. Lembeck, F. & Holzer, P. Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Naunyn-Schmiedeberg's Arch. Pharmacol. 310, 175-183 (1979).
4. Lembeck, F. et al. The non-peptide tachykinin antagonist, CP-96, 345, is a potent inhibitor of neurogenic inflammation. Br. J. Pharmacol. 105, 527-30 (1992).
5. Otsuka, M. & Yoshioka, K. Neurotransmitter functions of mammalian tachykinins. Physiol. Rev. 73, 229-308 (1993).
6. Bhoola, K.D., Figueroa, C.D. & Woerthy, K. Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol. Rev. 44, 1-80 (1992).
7. Matsas, R. et al. Substance P and [Leu]enkephalin are hydrolyzed by an enzyme in pig caudate synaptic membranes that is identical with the endopeptidase of kidney microvilli. Proc. Natl. Acad. Sci. USA 80, 3111-3115 (1983).
8. Matsas, R., Kenny, A.J. & Turner, A.J. The metabolism of neuropeptides: The hydrolysis of peptides, including enkephalins, tachykinins and their analogues, by endopeptidase-24.11. Biochem. J. 233, 433-440 (1984).
9. Lu, B. et al. Neutral endopeptidase modulation of septic shock. J. Exp. Med. 181, 2271-2275 (1995).
10. Geppetti, P, Sensory neuropeptide release by bradykinin: Mechanisms and patho-physiological implications. Regul. Pept. 47, 1-23 (1993).
11. Gee, N.S. et al. An immunoradiometric assay for endopeptidase-24.11 shows it to be a widely distributed enzyme in pig tissues. Biochem. J. 228, 119-126 (1985).
12. Matsas, R., Kenny, A.J. & Turner, A.J. An immunohistochemical study of endopeptidase-24.11 ('enkephalinase') in the pig nervous system. Neuroscience 18, 991-1012 (1986).
13. Bunnett, N.W. et al Distribution and abundance of neutral endopeptidase (EC 3.4.24.11) in the alimentary tract of the rat. Am. J. Physiol. 264, G497-G508 (1993).
14. Umeno, E. et al. Inhibition of the neutral endopeptidase potentiates neurogenic inflammation in the rat trachea. J. Appl. Physiol. 66, 2647-2652 (1989).
15. Lotvall, J.O. et al. Bradykinin-induced airway microvascular leakage is potentiated by captopril and phosphoramidon. Eur. J. Pharmacol. 200, 211-7 (1991).
16. Saria, A. & Lundberg, J.M. Evans blue fluorescence: Quantitative and morphological evaluation of vascular permeability in animal tissues. J. Neurosci. Methods 8, 41-49 (1983).
17. Joris, I. et al. Vascular labelling with Monastral blue B. Stain Technol. 57, 177-183 (1982).
18. Emonds-Alt, X. et al. In vitro and in vivo biological activities of SR1 40333, a novel potent non-peptide tachykinin NK1 receptor antagonist. Eur. J. Pharmacol. 250, 403-413 (1993).
19. Rhaleb, N.E. et al. Pharmacological characterization of a new highly potent B2 receptor antagonist (HOE 140: D-Arg-[Hyp3, Thi5, D-Tic7, Qic8] bradykinin). Eur. J. Pharmacol. 210, 115-120 (1992).
20. Bunnett, N.W. et al. Metabolism of gastrin and cholecystokinin by endopeptidase 24.11 from the pig stomach. Am. J. Physiol. 255, G676-G684 (1988).
21. Kenny, A.J. & Stephenson, S.L. Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide. FASEB Lett. 232, 1-8 (1988).
22. Gardiner, S.M. et al Effects of the neutral endopeptidase inhibitor, SQ 28,603, on regional haemodynamic responses to atrial natriuretic peptide or proendothelin-1 [1-38] in conscious rats. Br. J. Pharmacol. 106, 180-6 (1992).
23. Lifton, R.P. Molecular genetics of human blood pressure variation. Science 272, 666-680 (1996).
24. Hwang, L. et al. Downregulation of neutral endopeptidase (EC 3.4.24.11) in the inflamed rat intestine. Am. J. Physiol. 264, G735-G743 (1993).
25. Borson, D.B. et al. Neutral endopeptidase and neurogenic inflammation in rats with respiratory infections. J. Appl. Physiol. 66, 2653-2658 (1989).
26. Figini, M. et al. Substance P and bradykinin stimulate plasma extravasation in the mouse gastrointestinal tract and pancreas.Am. J. Physiol. 272, G785-G793 (1997).